Current Releases
Archived Releases
Media Coverage

2005 Archived Releases

December 22, 2005

NUCRYST Pharmaceuticals Corp. announces pricing for Initial Public Offering

December 2, 2005

NUCRYST Pharmaceuticals Corp. files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

September 7, 2005

NUCRYST Pharmaceuticals appoints David C. McDowell Vice President of Operations

August 15, 2005

NUCRYST Pharmaceuticals announces second quarter results

February 17, 2005

NUCRYST Pharmaceuticals announces year-end results

2004 Archived Releases

November 4, 2004

NUCRYST Pharmaceuticals announces third quarter results

September 7, 2004

Westaim's NUCRYST Pharmaceuticals reports Phase 2a clinical trial results of investigational drug in atopic dermatitis

May 27, 2004

NUCRYST Pharmaceuticals announces Scientific Advisory Board

May 5, 2004

NUCRYST Pharmaceuticals announces first quarter results

2003 Archived Releases

December 4, 2003

NUCRYST Pharmaceuticals begins first Phase 2 clinical trial of novel dermatology drug

November 4, 2003

NUCRYST Pharmaceuticals announces third quarter results

August 7, 2003

NUCRYST Pharmaceuticals posts record quarter

April 25, 2003

Westaim’s NUCRYST Pharmaceuticals to pursue new eczema drug

March 12, 2003

NUCRYST Pharmaceuticals announces additional European approvals

2002 Archived Releases

April 22, 2002

Westaim’s NUCRYST Pharmaceuticals appoints Paul J. Schechter to lead drug development and regulatory approval processes

2001 Archived Releases

November 1, 2001

Westaim’s NUCRYST to pursue pharmaceutical applications for its proven nanotechnology

May 9, 2001

Smith & Nephew acquires burn business and exclusive license to new wound care technology from Westaim Biomedical

February 21, 2001

Westaim Biomedical receives FDA Over-the-Counter clearance for Acticoat™ products

  • Investor Relations
  • Stock Quote
  • Leadership
  • Join Email Club